228 related articles for article (PubMed ID: 8755233)
1. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
[No Abstract] [Full Text] [Related]
2. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Irani J
Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Bochner BH
Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
[No Abstract] [Full Text] [Related]
4. [ BCG-immunotherapy and bladder cancer].
Rischmann P
Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
[No Abstract] [Full Text] [Related]
5. Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
Sylvester RJ
Eur Urol; 2009 Aug; 56(2):266-8; discussion 268-9. PubMed ID: 19427110
[No Abstract] [Full Text] [Related]
6. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
[No Abstract] [Full Text] [Related]
7. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
Böhle A; Bock PR
Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
[TBL] [Abstract][Full Text] [Related]
8. [Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index].
Nohales Taurines G; Cortadellas Angel R; Arango Toro O; Bielsa Gali O; Gelabert Mas A
Arch Esp Urol; 1996 Sep; 49(7):689-92. PubMed ID: 9020005
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
10. Treatment of superficial carcinoma of the bladder.
Paulson DF
Prog Clin Biol Res; 1984; 162B():193-209. PubMed ID: 6209720
[No Abstract] [Full Text] [Related]
11. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
12. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder.
Kaasinen E; Wijkström H; Rintala E; Mestad O; Jahnson S; Malmström PU
Scand J Urol; 2016 Oct; 50(5):360-8. PubMed ID: 27603424
[TBL] [Abstract][Full Text] [Related]
13. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
14. Management of flat carcinoma in situ of the bladder.
Whitmore WF
Prog Clin Biol Res; 1984; 162B():219-24. PubMed ID: 6504897
[No Abstract] [Full Text] [Related]
15. [Intravesical instillation for bladder tumors].
Rivière A; Ploussard G; Desgranchamps F
Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
[No Abstract] [Full Text] [Related]
16. [Fixed points and open questions in the treatment of superficial bladder carcinoma].
Altieri V
Arch Ital Urol Androl; 2006 Dec; 78(4 Suppl 1):3-5. PubMed ID: 17491547
[No Abstract] [Full Text] [Related]
17. Innovative approaches for superficial bladder tumors.
Oosterlinck W; Abi-Aad A
Acta Urol Belg; 1996 May; 64(2):31-2. PubMed ID: 8701806
[No Abstract] [Full Text] [Related]
18. Effects of intravesical chemotherapy and immunotherapy on semen analysis.
Raviv G; Pinthus JH; Shefi S; Mor Y; Kaufman-Francis K; Levron J; Weissenberg R; Ramon J; Madgar I
Urology; 2005 Apr; 65(4):765-7. PubMed ID: 15833524
[TBL] [Abstract][Full Text] [Related]
19. WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
Shelley M; Court JB; Kynaston HG; Wilt TJ; Coles B; Mason M
Cochrane Database Syst Rev; 2015 Nov; (11):CD003231. PubMed ID: 26544085
[No Abstract] [Full Text] [Related]
20. Bacillus Calmette-Guerin therapy for bladder carcinoma in situ: use in a clinical setting.
Skaugen P
Urol Nurs; 1997 Jun; 17(2):69-71. PubMed ID: 9239141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
